Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

Tazemetostat [1403254-99-8]

Imprimir

Referência HY-13803-5mg

Tamanho : 5mg

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Marca : MedChemExpress

Solicitar mais informações

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Tazemetostat Chemical Structure

CAS No. : 1403254-99-8

Size	Stock	Quantité
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	En stock	Estimated Time of Arrival: December 31
500 mg	Obtenir un devis
1 g	Obtenir un devis

or Bulk Inquiry

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Based on 65 publication(s) in Google Scholar

Other Forms of Tazemetostat:

Tazemetostat trihydrochloride Obtenir un devis
Tazemetostat hydrochloride Obtenir un devis
Tazemetostat hydrobromide Obtenir un devis
Tazemetostat (Standard) Obtenir un devis

: Tazemetostat purchased from MedChemExpress. Usage Cited in: Nat Struct Mol Biol. 2018 Mar;25(3):225-232. [Abstract]; Western blots of extracts from E14 mESCs treated with 10 μM. EPZ6438 EZH2 inhibitor for 7 d and sampled at time points following inhibitor washout. Blots are probed with the indicated antibodies.

: Tazemetostat purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499. [Abstract]; Immunoblotting for N1-ICD (n=3) in mouse podocytes exposed to 10 μM EPZ-6438 for 48 hours.

: Tazemetostat purchased from MedChemExpress. Usage Cited in: Toxins (Basel). 2017 May 16;9(5). pii: E162. [Abstract]; Cells are treated with LeTx in the presence or absence of GSK-J4 or EPZ-6438 for 48 h. H3K27me3 level is analyzed by Western blotting.

Description

IC₅₀ & Target^[1]

EZH2

Cellular Effect

Cell Line	Type	Value	Description	References
ASPC1	IC₅₀	> 30 μM Compound: EPZ6438	Antiproliferative activity against human ASPC1 cells assessed as cell growth inhibition incubated for 6 days by MTS assay Antiproliferative activity against human ASPC1 cells assessed as cell growth inhibition incubated for 6 days by MTS assay	[PMID: 35500243]
BT-549	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
Daudi	GI₅₀	> 10 μM Compound: 1; EPZ-6438	Antiproliferative activity against human Daudi cells expressing wild type EZH2 assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human Daudi cells expressing wild type EZH2 assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]
G-401	EC₅₀	0.2 μM Compound: 4; EPZ-6438; Tazemetostat	Inhibition of methyltransferase activity of EZH2 in human G401 cells assessed as H3K27 trimethylation after 4 hrs by ELISA Inhibition of methyltransferase activity of EZH2 in human G401 cells assessed as H3K27 trimethylation after 4 hrs by ELISA	[PMID: 26769278]
HCT-116	IC₅₀	> 20 μM Compound: 5; EPZ6438	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
HeLa	IC₅₀	0.02 μM Compound: EPZ-6438	Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method	[PMID: 26189078]
HK-2	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human HK-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HK-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
HL-60	IC₅₀	> 20 μM Compound: 5; EPZ6438	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
HL-60	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
K562	IC₅₀	59.2 μM Compound: 2; EPZ-6438	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35569264]
KARPAS-422	IC₅₀	0.012 μM Compound: 5; EPZ-6438	Antiproliferative activity against human KARPAS422 cells harboring monoallelic Y641N EZH2 mutation assessed as reduction in cell viability measured every 3 to 4 days up to 14 days by Beckman Coulter-based method Antiproliferative activity against human KARPAS422 cells harboring monoallelic Y641N EZH2 mutation assessed as reduction in cell viability measured every 3 to 4 days up to 14 days by Beckman Coulter-based method	[PMID: 28092155]
KARPAS-422	GI₅₀	0.09 μM Compound: 1; EPZ-6438	Antiproliferative activity against human KARPAS-422 cells harboring EZH2 Y641N mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human KARPAS-422 cells harboring EZH2 Y641N mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]
L02	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MCF-10A	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MCF-10A	IC₅₀	> 50 μM Compound: Taz	Antiproliferative activity against human MCF-10A cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 34455779]
MCF7	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MCF7	IC₅₀	> 50 μM Compound: Taz	Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 34455779]
MDA-MB-231	IC₅₀	> 20 μM Compound: 5; EPZ6438	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
MDA-MB-231	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MDA-MB-231	IC₅₀	44.45 μM Compound: Taz	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 34455779]
MDA-MB-468	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MDA-MB-468	IC₅₀	46.76 μM Compound: Taz	Antiproliferative activity against human MDA-MB-468 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 34455779]
MV4-11	IC₅₀	> 20 μM Compound: 5; EPZ6438	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
MV4-11	IC₅₀	> 40 μM Compound: Tazemetostat	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
Pfeiffer	GI₅₀	0.002 μM Compound: 1; EPZ-6438	Antiproliferative activity against human Pfeiffer cells harboring EZH2 A677G mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human Pfeiffer cells harboring EZH2 A677G mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]
Pfeiffer	IC₅₀	38 nM Compound: EPZ-6438	Cytotoxicity against human Pfeiffer cells assessed as decrease in cell viability after 5 days by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human Pfeiffer cells assessed as decrease in cell viability after 5 days by CellTiter-Glo reagent based luminescence assay	[PMID: 29456795]
Raji	GI₅₀	> 10 μM Compound: 1; EPZ-6438	Antiproliferative activity against human Raji cells expressing wild type EZH2 assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human Raji cells expressing wild type EZH2 assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]
SUD4	GI₅₀	3.39 μM Compound: 1; EPZ-6438	Antiproliferative activity against human SU-DHL-4 cells harboring EZH2 Y641S mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human SU-DHL-4 cells harboring EZH2 Y641S mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]
SU-DHL10	IC₅₀	> 20 μM Compound: 5; EPZ6438	Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
SU-DHL-6	GI₅₀	1.05 μM Compound: 1; EPZ-6438	Antiproliferative activity against human SU-DHL-6 cells harboring EZH2 Y641N mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human SU-DHL-6 cells harboring EZH2 Y641N mutant assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]
U2932	GI₅₀	> 10 μM Compound: 1; EPZ-6438	Antiproliferative activity against human U2932 cells expressing wild type EZH2 assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay Antiproliferative activity against human U2932 cells expressing wild type EZH2 assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	[PMID: 34664960]

In Vitro

Tazemetostat (EPZ-6438) inhibits multi wild-type and mutant lymphoma cell lines proliferation with IC₅₀s of 0.49 nM-7.6 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	Wild-type and mutant lymphoma cell lines
Concentration:	0.49-7.6 μM
Incubation Time:	11 days
Result:	Inhibited DOHH-2 cell (EZH2 wild-type; IC₅₀=1.7 μM), Farage cell (EZH2 wild-type; IC₅₀=99 nM), OCI-LY19 cell (EZH2 wild-type; IC₅₀=6.2 μM), Toledo cell (EZH2 wild-type; IC₅₀=7.6 μM), KARPAS-422 (EZH2 Y646N; IC₅₀=1.8 nM), Pfeiffer (EZH2 A682G; IC₅₀=0.49 nM), RL cell line (EZH2 Y646N; IC₅₀=5.8 μM), SU-DHL-10 (EZH2 Y646F; IC₅₀=5.8 nM), SU-DHL-6 (EZH2 Y646N; IC₅₀=4.7 nM), WSU-DLCL2 (EZH2 Y646F; IC₅₀=8.6 nM) proliferation.

In Vivo

Tazemetostat (EPZ-6438; 250 or 500 mg/kg twice daily for 21-28 days) practically eliminates the fast-growing G401 tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice bearing s.c. G401 xenografts^[1]
Dosage:	125 mg/kg, 250 mg/kg and 500 mg/kg
Administration:	Oral administration; twice daily; 28 days
Result:	Eliminated the fast-growing G401 tumors.

Masse moléculaire

572.74

Formule

C₃₄H₄₄N₄O₄

CAS No.

1403254-99-8

Appearance

Solid

Color

White to light yellow

SMILES

O=C(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(N(CC)C4CCOCC4)=C1C)NCC5=C(C)C=C(C)NC5=O

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvant et solubilité

In Vitro:

DMSO : 31.25 mg/mL (54.56 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

0.1 M HCL : 14.29 mg/mL (24.95 mM; ultrasonic and adjust pH to 5 with HCl)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7460 mL	8.7300 mL	17.4599 mL
5 mM	0.3492 mL	1.7460 mL	3.4920 mL
10 mM	0.1746 mL	0.8730 mL	1.7460 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité
Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (4.36 mM); Clear solution
Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.36 mM); Clear solution
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.1% Tween-80 in Saline water
Solubility: 50 mg/mL (87.30 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureté et documentation

Purity: 99.93%

Select Batch:

SDS (393 KB)

COA (252 KB) HNMR (206 KB) LCMS (120 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Knutson SK, et, al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferaseEZH2. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

0.1 M HCL / DMSO	1 mM	1.7460 mL	8.7300 mL	17.4599 mL	43.6498 mL
	5 mM	0.3492 mL	1.7460 mL	3.4920 mL	8.7300 mL
	10 mM	0.1746 mL	0.8730 mL	1.7460 mL	4.3650 mL
	15 mM	0.1164 mL	0.5820 mL	1.1640 mL	2.9100 mL
	20 mM	0.0873 mL	0.4365 mL	0.8730 mL	2.1825 mL
DMSO	25 mM	0.0698 mL	0.3492 mL	0.6984 mL	1.7460 mL
	30 mM	0.0582 mL	0.2910 mL	0.5820 mL	1.4550 mL
	40 mM	0.0436 mL	0.2182 mL	0.4365 mL	1.0912 mL
	50 mM	0.0349 mL	0.1746 mL	0.3492 mL	0.8730 mL

Tazemetostat Related Classifications

Epigenetics Apoptosis
Histone Methyltransferase Apoptosis

Help & FAQs

Keywords:

Tazemetostat1403254-99-8EPZ-6438 E-7438EPZ6438EPZ 6438E7438E 7438E-7438Histone MethyltransferaseApoptosisEZH2PRC2EZH1epigeneticcancerInhibitorinhibitorinhibit

Tazemetostat [1403254-99-8]

Referência HY-13803-5mg

Contactar o distribuidor local :

Marca : MedChemExpress

Contactar o distribuidor local :

Other Forms of Tazemetostat:

Tazemetostat Related Antibodies

Calculateur de molarité

Calculateur de dilution

Complete Stock Solution Preparation Table

Tazemetostat Related Classifications

Keywords:

Você também pode estar interessado nos seguintes produtos: